Venture Medical Announces Strategic Partnership with Plasmacure to Bring Groundbreaking Cold Plasma Therapy for Chronic Wounds to the U.S. Market

Venture Medical, LLC, a leading provider of advanced wound care solutions, is proud to announce a strategic development and distribution agreement in principle with Plasmacure B.V., the Netherlands-basedMedTech innovator behind the revolutionary PLASOMA cold plasma system for chronic wound treatment.

This agreement will introduce a new technology that has already demonstrated strong results in promoting wound healing to the UnitedStates.   Under the terms of the agreement, Venture Medical will lead the FDA approval process. Once regulatory approval has been secured, Venture Medical will serve as Plasmacure’s exclusiveU.S. commercialization partner, supporting market entry, clinician education, and nationwide distribution of the CE-marked PLASOMA cold plasma device.

“The Plasoma cold plasma system represents the kind of patient-first innovation our industry needs,” said John Schroeder, VentureMedical CEO. “At Venture Medical we are willing to invest in long-term solutions for patients who currently have few good options for treating difficult-to-heal wounds.”

Plasmacure’s PLASOMA system delivers cold plasma derived from room air directly to chronic wounds through a unique flexible pad, safely initiating multiple mechanisms of action which are well known to speed healing.  As rates of diabetic foot ulcers and other non-healing wounds continue to rise in the U.S., this system will offer a timely and effective response.

More details about the commercial path for PLASOMA and educational initiatives around the technology are forthcoming.

To learn more about PLASOMA or to learn more about the ability to partner with Venture Medical,  visit www.venturemedical1.com or www.plasmacure.nl.

‍

‍